Press Releases & Media Statements

Developing treatments for people with mental health conditions

laboratory equipment

Boehringer Ingelheim collaborates with Circle Pharma

Scientist at work

Boehringer receives U.S. FDA Breakthrough Therapy designation for MASH

Lab Research

Topline results from Boehringer's Phase III IPF Study

A female physician reviews information on a tablet

Positive results reported in HER2 mutated lung cancer

picture of a researcher in a white lab coat and lab goggles

Boehringer Ingelheim to unveil oncology research at WCLC

picture of a woman in a white lab coat and lab goggles holding a pipette tool

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Lab workers

New affordability initiative with GoodRx for our biosimilar

People on computer

New effort to help improve C-R-M health outcomes

Results from Phase II MASH trial presented at EASL 2024

Liver graphic

Boehringer inhalers now available at $35 a month for eligible patients

Woman with brown hair standing outside in front of blue sky

New agreement with Quallent expands biosimilar access

Pharmacist talking with patient

Improving Access to Clinical Trials

Scientists

FDA Approves Additional Formulation of Our Biosimilar

Doctor speaking with patient.

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.

Results announced from EMPACT-MI phase III trial

Scientists working together

New FDA approval for the treatment of GPP

photo of male researcher working in a lab

Update on sNDA for fibrosing ILD in children and adolescents

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Top-line Phase II Data for treatment of MASH

Liver Illustration

National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)

photo of female physician in conversation with colleagues

Investigational Compound Granted FDA Orphan Drug Designation

photo of researcher

Promising Phase II Results in Chronic Kidney Disease

Kidney Illustration

AI-Driven Model Validated to Predict Risk of CKD Progression

Kidney Illustration

Media Contacts

Head, U.S. Communications Human Pharma

900 Ridgebury Rd.
P.O. Box 368
Ridgefield, CT 06877

michele.baer@boehringer-ingelheim.com

Head, U.S. Communications
Animal Health

Phone +1 (913) 620-0026

rene.ward@boehringer-ingelheim.com

U.S. Communications

Phone +1 (203) 791-6487

belinda.martin@boehringer-ingelheim.com

Boehringer Ingelheim Animal Health USA Inc.
U.S. Communications

Phone +1 (516) 527-5456

christine.jones@boehringer-ingelheim.com